All Stories

  1. Comparison of Efficiency and Side Effects of Daily and Alternate Day Oral Iron
  2. Comment on Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina 2022, 58, 874
  3. A Signet Ring Cell Carcinoma Presented as Refractory Acquired Thrombotic Thrombocytopenic Purpura
  4. A rare case of diffuse large B-cell lymphoma-associated hemophagocytic lymphohistiocytosis
  5. In vitro analysis of the renin–angiotensin system and inflammatory gene transcripts in human bronchial epithelial cells after infection with severe acute respiratory syndrome coronavirus
  6. Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)
  7. Splenic Marginal Zone Lymphoma in Turkey: Association With Hepatitis B Instead Of Hepatitis C Virus As An Etiologic and Possible Prognostic Factor-Multicenter Cohort Study
  8. The factors affecting early death in newly diagnosed APL patients
  9. The impact of early versus late platelet and neutrophil recovery after induction chemotherapy on survival outcomes of patients with acute myeloid leukemia
  10. Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma
  11. Indications and outcomes of splenectomy for hematological disorders
  12. The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia
  13. Fibrosis Development, Leukemic Transformation and Secondary Malignancies Complicating the Clinical Course of Essential Thrombocythemia
  14. Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia
  15. Pediatric Chemotherapeutic Regimen (BFM-95) is Superior for Overall Survival in Adult Acute Lymphoblastic Leukemia
  16. Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia
  17. Combination of novoseven and feiba in hemophiliac patients with inhibitors
  18. Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients
  19. Immunosuppression-associated posterior reversible encephalopathy syndrome in an acute leukemia case
  20. Extramedullary relapses of acute leukemias after allogeneic hematopoietic stem cell transplantation: clinical features, cumulative incidence, and risk factors
  21. Leukapheresis do not improve early death rates in acute myeloid leukemia patients with hyperleukocytosis
  22. Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in Remission
  23. Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines
  24. Experience with Pegylated Interferon α-2a in 30 Patients Diagnosed with Hematologic Neoplasms
  25. Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma
  26. The Prognosis of Adult Burkitt’s Cell Leukemia in Real-Life Clinical Practice
  27. Ultrastructural analyses of the novel chimeric hemostatic agent generated via nanotechnology, ABS nanohemostat, at the renal tissue level
  28. Clinical associations, biological risk factors and outcomes of cerebral venous sinus thrombosis
  29. The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases.
  30. Poster Session TPS 1-18
  31. Idelalisib at the Crossroads of B-Cell Lymphoproliferative Disorders.
  32. Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case
  33. The Impact of Iron Overload on Transplant-Related Complications and Prognosis of Acute Leukemias.
  34. Reply
  35. Chimeric antigen receptor T cell treatment in hematologic malignancies
  36. Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids
  37. Generic Imatinib Mesylate is as Effective as Original Glivec in the Clinical Management of CML.
  38. Rational diagnoses of diabetes: the comparison of 1,5-anhydroglucitol with other glycemic markers
  39. Extramedullary relapses after allogeneic stem cell transplantation for leukemia: Clinical characteristics, cumulative incidence and risk factors.
  40. Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib
  41. Rebound Thrombocytosis following Induction Chemotherapy Is an Independent Predictor of a Good Prognosis in Acute Myeloid Leukemia Patients Attaining First Complete Remission
  42. Erdheim-Chester Disease: A Case Report
  43. Diffuse Large B Cell Lymphoma with Extensive Cutaneous Relapse
  44. Late Onset and Protracted Course of Steroid Refractory Chronic Graft-versus-Host Disease
  45. Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case
  46. Giant Hemophilic Pseudotumor of the Iliopsoas: Case Report
  47. Massive Life-Threatening Hemorrhages Due to Toxic Oral Intake of 3750 Mg Dabigatran Etexilate As a Suicide Attempt and the Clinical Management
  48. Prognostic Factors for Survival of Elderly Patients with Acute Myeloid Leukemia after Intensive Chemotherapy: Validation of 3 Popular Prognostic Models
  49. Rebound Thrombocytosis Is an Independent Predictor of Good Prognosis in AML Patients Attaining First Complete Remission
  50. PP-025 ADVANCED PHASE CHRONIC MYELOID LEUKEMIA RESISTANT TO IMATINIB, NILOTINIB, DASATINIB AND INTERFERON WITHOUT ABL KINASE MUTATION
  51. PP-020 AN ESSENTIAL THROMBOCYTOSIS CASE, WHICH TRANSFORMED TO ACUTE MYELOID LEUKEMIA AFTER 12 YEARS
  52. PP-021 ASHERMAN SYNDROME WITH FACTOR 7 DEFICIENCY: CASE REPORT
  53. PP-058 MYASTENIA GRAVIS AND WALDENSTROM MACROGLOBULINEMIA: IS COMMON IMMUNOLOGIC MECHANISM POSSIBLE?
  54. PP-063 TWO CASES WITH PRIMARY IMMUNE DEFICIENCY AND NEOPLASTIC LYMPHOID PROLIFERATION